The global cancer anorexia cachexia syndrome drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Cancer cachexia is a complex metabolic disease syndrome characterised by low body weight (particularly muscle mass) and anorexia in cancer patients. Cancer cachexia has been shown to have a major impact on patients’ quality of life (QOL) and prognosis. The term cachexia refers to a loss of body mass, both lean and fat, as a result of a disease state, in this case cancer. Patients with such signs and symptoms have a shorter survival time, have a poor response to chemotherapeutic drugs, and are more toxic to agents. Furthermore, cancer anorexia/cachexia is frequently linked to weakness, weariness, and low quality of life.
To Request a Sample of our Report on Cancer Anorexia Cachexia Syndrome Drug Market: https://www.omrglobal.com/request-sample/cancer-anorexia-cachexia-syndrome-drug-market
The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including partnerships and collaborations, mergers and acquisitions, geographical expansion, and new product launches, to remain competitive in the marketplace. For instance, Adlumiz (generic name: anamorelin hydrochloride) Tablet 50mg (Adlumiz), a ghrelin receptor agonist, was launched in Japan in April 2021 for the treatment of cancer cachexia in malignant tumors of non-small cell lung cancer, gastric cancer, pancreatic cancer, or colorectal cancer. Adlumiz is a ghrelin receptor agonist that is selective, unique, and orally active. The stomach secretes ghrelin, which is an endogenous peptide. Ghrelin stimulates several pathways in the positive regulation of body weight, muscle mass, hunger, and metabolism once it binds to its receptor. Adlumiz has been proven to increase body weight, the muscular mass, and hunger in cancer patients with cachexia.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2020-2028
Segment Covered-
- By Product Type
- By Distribution Channel
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape- Ono Pharmaceutical Co., Ltd., and Pfizer Inc, among others.
(Get 15% Discount on Buying this Report)
A full Report of Global Incubator Devices Market is Available @ https://www.omrglobal.com/industry-reports/cancer-anorexia-cachexia-syndrome-drug-market
Global Anorexia Cachexia Syndrome Drug Market Report by Segment
By Treatment Type
- Progestogens
- Corticosteroids
- Combination therapies
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Anorexia Cachexia Syndrome Drug Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
